BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28456090)

  • 21. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
    Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    Ann Oncol; 2009 Jul; 20(7):1223-9. PubMed ID: 19282466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
    Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer.
    Okabe H; Tsunoda S; Hosogi H; Hisamori S; Tanaka E; Tanaka S; Sakai Y
    Ann Surg Oncol; 2015 Nov; 22(12):3954-61. PubMed ID: 25777087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
    Lindsay CR; Blackhall FH; Carmel A; Fernandez-Gutierrez F; Gazzaniga P; Groen HJM; Hiltermann TJN; Krebs MG; Loges S; López-López R; Muinelo-Romay L; Pantel K; Priest L; Riethdorf S; Rossi E; Terstappen L; Wikman H; Soria JC; Farace F; Renehan A; Dive C; Besse B; Michiels S
    Eur J Cancer; 2019 Aug; 117():60-68. PubMed ID: 31254940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Van Cutsem E; Muro K; Cunningham D; Bodoky G; Sobrero A; Cascinu S; Ajani J; Oh SC; Al-Batran SE; Wainberg ZA; Wijayawardana SR; Melemed S; Ferry D; Hozak RR; Ohtsu A;
    Eur J Cancer; 2020 Mar; 127():150-157. PubMed ID: 32014812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of a semi-automated NanoVelcro system in capturing circulating tumor cells and evaluating their prognostic value for gestational choriocarcinoma.
    Hou M; Zheng Y; Ding Z; He S; Xu M; Chen X; Zhang H; Zeng C; Sun C; Jiang W; Wang H; Shen H; Zhang Y; Liu J; Sun S; Jiang N; Cui Y; Sun Y; Chen Y; Cao J; Wang C; Li M; Zhang Y; Wang J; Lin M; Ke Z
    Biomater Sci; 2019 Feb; 7(3):1200-1210. PubMed ID: 30656300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.
    Riethdorf S; Müller V; Loibl S; Nekljudova V; Weber K; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Schem C; von Minckwitz G; Untch M; Pantel K
    Clin Cancer Res; 2017 Sep; 23(18):5384-5393. PubMed ID: 28679772
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study.
    Mazard T; Cayrefourcq L; Perriard F; Senellart H; Linot B; de la Fouchardière C; Terrebonne E; François E; Obled S; Guimbaud R; Mineur L; Fonck M; Daurès JP; Ychou M; Assenat E; Alix-Panabières C
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
    Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
    Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.